SynthesisFrontiers in clinical diabetes and healthcare2026
Safety evaluation of Sodium-glucose cotransporter 2 inhibitors for cancer risk in specific populations: systematic review and meta-analysis.
Synthesis in Frontiers in clinical diabetes and healthcare, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, commonly treated for Type 2 diabetes mellitus (T2DM), have demonstrated benefits in reducing cardiovascular and renal events. However, heart failure (HF) and chronic kidney disease (CKD) are prevalent comorbidities in T2DM. This study aims to assess the long-term safety of SGLT2 inhibitor, particularly concerning cancer risk in these populations. Methods: We searched PubMed, CENTRAL, Web of Science, and ClinicalTrials.gov for studies published up to April 16, 2024. The primary outcome was overall cancer risk, with secondary outcomes focused on specific cancer types. Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated. This meta-analysis was registered in PROSPERO (CRD42024560310). Results: 28 randomized controlled trials involving 98,297 participants were included. SGLT2 inhibitors did not increase overall cancer risk (RR = 1.05, 95% CI [0.99, 1.12]). Furthermore, the use of SGLT2 inhibitors does not exhibit a significant association with the risk of several common cancer types. Subgroup analyzes indicated that SGLT2 inhibitors appeared to be temporarily safe in patients with HF (RR = 1.03, 95% CI [0.91, 1.18]), CKD (RR = 1.02, 95% CI [0.90, 1.16]) and T2DM related comorbidities. Additionally, none of the different types of SGLT2 inhibitors increase the overall cancer risk. Conclusions: SGLT2 inhibitors do not appear to increase overall cancer risk, including several common cancers such as breast cancer and bladder cancer. The use of SGLT2 inhibitors in different patient populations is temporarily safe. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024560310.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.